Bausch + Lomb Posts Q1-2017 Revenues of $1.15 Billion in ‘Solid Quarter’

May 12, 2017: By Joan McKenna

BauschBausch + Lomb posted flat revenues of $1.15 billion on a reported basis (+4 percent in constant currency) in Q1-2017 and provided parent Valeant Pharmaceuticals with a “solid quarter,” company officials announced May 9.

The eye care segment’s revenues accounted for more than half of Valeant’s $2.1 billion in revenues during the quarter.

Bausch + Lomb, based in Bridgewater, New Jersey, saw a 1 percent increase in revenues over Q1-2016’s  $1.146 billion in revenues.

Paul Herendeen, chief financial officer, said Bausch + Lomb’s global ophthalmic pharmaceutical revenues were up 1 percent (+3 cc), with international units offsetting a slight decline in US units.

The global consumer business showed modest revenue growth, while global surgical and vision care declined, he said. Bausch + Lomb completed its acquisition of retinal device maker Synergetics in October 2015 and saw a subsequent boost in surgical sales due to the deal.

Valeant Chief Executive Joseph Papa said Bausch + Lomb’s positive first quarter resulted in part from price increases of about 1.5 percent.

Valeant said Bausch + Lomb’s PreserVision and Ocuvite are the number one ocular vitamin brands globally, while Biotrue is the number one multipurpose solution brand, and PreserVision AREDS 2 Formula (120 count) is the top selling vitamin item in the US.

Bausch + Lomb’s milestones during the quarter include receiving US FDA 510(k) clearances in April for the Stellaris Elite dual cataract/vitrectomy system and Vitesse hypersonic vitrector. The company has FDA target actions dates for Vyzulta (glaucoma) in August 2017 and Luminesse (eye redness) in December 2017.

Growth was primarily driven by increases in volume outside the US, particularly in Europe, the Middle East, South Africa, Asia, and Australia, of $59 million. This was partially offset by declines in US volume of $10 million.

Volume and pricing gains were partially offset by the unfavorable impact of foreign currencies of $41 million and the impact of divestitures and discontinuations of $21 million.

Valeant’s long-term debt now stands at $28.5 billion, with debt reduction continuing to be a priority. Valeant said it has reduced its principal amount of debt by $3.6 billion since Q1-2016.

 

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022